GLP-1 Drugs: Impact on Self-Insured Employer Health Costs and Coverage Strategies

Understanding GLP-1 Drugs and Their Financial Impact

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and liraglutide, have gained significant attention for their effectiveness in treating type 2 diabetes and obesity. While these medications can improve employee health outcomes, they come with a high price tag that self-insured employers need to manage.

Current Spending on GLP-1 Drugs

Self-insured employers are seeing substantial increases in their pharmacy benefit costs due to GLP-1 medications. Here are key spending insights:

• Cost Per Prescription: The average cost for a 30-day supply of GLP-1 drugs ranges from $800 to $1,200.
• Utilization Rates: A study showed that approximately 8% of employees in self-insured plans were prescribed GLP-1 drugs in 2022, with this figure expected to rise as more employers include these medications in their formularies.
• Projected Annual Spending: By 2025, employers could face an estimated $4 billion in excess spending on GLP-1 drugs if utilization doubles, reflecting a potential increase in total healthcare costs by an average of 3% to 5%.

Effective Guardrails for Managing Costs

To mitigate the financial impact of GLP-1 drugs, self-insured employers can implement several guardrails:

• Prior Authorization: Require physicians to justify the need for GLP-1 medications before approval. This can reduce unnecessary prescriptions and align treatment with clinical guidelines.
• Step Therapy: Implement a step therapy protocol whereby employees are required to try lower-cost alternatives before moving to GLP-1 drugs. For instance, requiring metformin use prior to GLP-1 approval can save costs.
• Cost-Share Adjustments: Adjust employee cost-sharing structures. For example, charging a higher copayment for GLP-1 drugs can discourage overutilization while still providing access for those who need them.

Structuring a Coverage Policy

When developing a coverage policy for GLP-1 drugs, consider the following components:

1. Formulary Placement: Position GLP-1 drugs in a way that encourages appropriate use. Placing them in a preferred tier alongside other diabetic medications can promote adherence while managing costs.

2. Eligibility Criteria: Define clear clinical criteria for coverage. For instance:

   • Must have a diagnosis of type 2 diabetes or obesity with a BMI of 30 or higher.
   • Documented failure of lifestyle interventions and lower-cost medication options.

3. Incentives for Health Improvement: Offer wellness incentives for employees who engage in health improvement programs, such as weight loss or diabetes management programs. This can reduce overall costs and improve health outcomes.

4. Data Transparency: Utilize data analytics to track usage patterns and costs associated with GLP-1 drugs. This allows for real-time adjustments to coverage policies based on actual spending trends.

Case Study: Successful Implementation

A self-insured employer in the manufacturing sector implemented a comprehensive coverage policy that included the following strategies:

• Prior Authorization and Step Therapy: After introducing these measures, the employer reduced GLP-1 prescriptions by 30% over one year.
• Cost-Share Adjustments: Increased employee copayment for GLP-1s from $30 to $75, leading to a 25% decrease in new prescriptions.
• Wellness Program: Launched a diabetes management program that incentivized participation with a $500 health savings account contribution, resulting in a 15% reduction in overall diabetes-related costs.

The Importance of Continuous Monitoring

Continuous monitoring is crucial for managing GLP-1 drug costs effectively. Regularly reviewing utilization data can help you make informed decisions about your coverage policy. Consider the following metrics:

• Prescription Volume Trends: Track changes in the number of new prescriptions for GLP-1 drugs.
• Employee Health Outcomes: Measure improvements in health metrics such as average blood glucose levels and weight reductions.
• Overall Pharmacy Spend: Analyze the impact of GLP-1 drug spending on total pharmacy costs over time.

Bottom Line

Self-insured employers face significant financial challenges with the rising use of GLP-1 drugs. By implementing strategic guardrails, structuring thoughtful coverage policies, and continuously monitoring data, employers can manage costs effectively. Start by assessing your current pharmacy benefit structure and consider integrating prior authorization and step therapy protocols to curb unnecessary spending while still supporting employee health initiatives.